A phase III study of Roxadustat for the treatment of anemia in patients with myelodysplastic syndromes (MDS)
Phase of Trial: Phase III
Latest Information Update: 09 May 2017
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors FibroGen
- 09 May 2017 According to a FibroGen media release, the company received approval from FDA to conduct this trial. This trial is expected to initiate in the third quarter of 2017.
- 31 Mar 2017 According to a FibroGen media release, the company anticipates initiating this trial in the first half of 2017.
- 06 Mar 2017 New trial record